An Alzheimer’s drug fails, but many others still in testing

Another major Alzheimer's drug study has failed, leaving patients and families wondering if there ever will be a treatment to slow or reverse the most common form of dementia, which afflicts more than 5 million in the United States alone. Eli Lilly & Co. said Wednesday that solanezumab (sol-ah-NAYZ-uh-mab) failed to slow mental decline in people with mild Alzheimer's. The drug is still being tried in two other studies, and at least 18 other drugs are in late-stage testing, including several

Another major Alzheimer's drug study has failed, leaving patients and families wondering if there ever will be a treatment to slow or reverse the most common form of dementia, which afflicts more than 5 million in the United States alone. Eli Lilly & Co. said Wednesday that solanezumab (sol-ah-NAYZ-uh-mab) failed to slow mental decline in people with mild Alzheimer's. The drug is still being tried in two other studies, and at least 18 other drugs are in late-stage testing, including several sim…